文献速递妇科

用于检测浆液性卵巢癌的自身抗体生物标志物

Autoantibody biomarkers for the detection of serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-04-18

本研究利用高密度可编程蛋白微阵列(NAPPA)筛选浆液性卵巢癌患者血清中的肿瘤抗原相关自身抗体(TAAb),经多阶段验证后构建了包含11种TAAb的分类器,在98%特异性下对高级别浆液性卵巢癌的敏感性为45%,作者认为这些是潜在循环生物标志物,需在更大临床队列中验证。

要点

  • 研究分三阶段筛选并验证血清TAAb,最终鉴定出11种TAAb组合。
  • 11种TAAb组合区分高级别浆液性卵巢癌与健康对照的敏感性为45%(特异性98%)。
  • 作者认为这些是潜在循环生物标志物,需在更大临床队列中验证。

核心结论

  • 这些TAAb是检测浆液性卵巢癌的潜在循环生物标志物,需在更大临床队列中验证。

研究设计与样本

  • 研究用含10,247种抗原的高密度可编程蛋白微阵列(NAPPA)检测浆液性卵巢癌患者(30例)与健康对照(30例)血清中结合的IgG。
  • 鉴定出735种有希望的肿瘤抗原后,用独立浆液性卵巢癌血清(30例)、良性疾病对照(30例)和健康对照(30例)进行评估。
  • 鉴定出39种潜在肿瘤自身抗原后,用正交可编程ELISA平台在共153份血清样本(63例病例、30例良性疾病对照、60例健康对照)中评估。

主要发现

  • 最终鉴定出11种TAAb(ICAM3、CTAG2、p53、STYXL1、PVR、POMC、NUDT11、TRIM39、UHMK1、KSR1和NXF3)。
  • 11种TAAb组合区分高级别浆液性卵巢癌病例与健康对照的敏感性为45%(特异性98%)。

关键数值与推荐

  • 敏感性45%系在特异性98%条件下计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需在更大临床队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Objective The purpose of this study was to identify a panel of novel serum tumor antigen-associated autoantibody (TAAb) biomarkers for the diagnosis of high-grade serous ovarian cancer. METHODS: To detect TAAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n=30 cases/30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens and evaluated these with an independent set of serous ovarian cancer sera (n=30 cases/30 benign disease controls/30 healthy controls). Thirty-nine potential tumor autoantigens were identified and evaluated using an orthogonal programmable ELISA platform against a total of 153 sera samples (n=63 cases/30 benign disease controls/60 healthy controls). Sensitivities at 95% specificity were calculated and a classifier for the detection of high-grade serous ovarian cancer was constructed. RESULTS: We identified 11-TAAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished high-grade serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 98% specificity. CONCLUSION: These are potential circulating biomarkers for the detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Katchman BA, Chowell D, Wallstrom G, et al. Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol. 2017. PMID: 28427776. doi:10.1016/j.ygyno.2017.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。